Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

Executive Summary

Kite reported interim results for KTE-C19 from the ZUMA-1 study that showed efficacy consistent with earlier results without the deaths from neurotoxicity that have plagued Juno, but Juno’s latest CAR-T offering may carry fewer safety concerns.

Advertisement

Related Content

What's Gilead Getting From Kite For Nearly $12bn?
BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again
New Interim CAR-T Data Support Kite’s BLA Submission Plans

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel